BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of $10.75 million. The enterprise value is $5.12 million.
Important Dates
The last earnings date was Monday, March 23, 2026, before market open.
| Earnings Date | Mar 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.61 billion shares outstanding. The number of shares has increased by 105.76% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.61B |
| Shares Change (YoY) | +105.76% |
| Shares Change (QoQ) | +2.12% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 3.97% |
| Float | 2.50B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.11 |
| Forward PS | n/a |
| PB Ratio | 0.46 |
| P/TBV Ratio | 5.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.43.
| Current Ratio | 1.95 |
| Quick Ratio | 1.76 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.22 |
Financial Efficiency
Return on equity (ROE) is -11.01% and return on invested capital (ROIC) is -20.74%.
| Return on Equity (ROE) | -11.01% |
| Return on Assets (ROA) | -16.11% |
| Return on Invested Capital (ROIC) | -20.74% |
| Return on Capital Employed (ROCE) | -35.74% |
| Weighted Average Cost of Capital (WACC) | 8.20% |
| Revenue Per Employee | $49,167 |
| Profits Per Employee | -$48,958 |
| Employee Count | 24 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.35% in the last 52 weeks. The beta is 0.46, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -26.35% |
| 50-Day Moving Average | 2.77 |
| 200-Day Moving Average | 3.48 |
| Relative Strength Index (RSI) | 30.55 |
| Average Volume (20 Days) | 16,968 |
Short Selling Information
The latest short interest is 167,577, so 3.86% of the outstanding shares have been sold short.
| Short Interest | 167,577 |
| Short Previous Month | 169,422 |
| Short % of Shares Out | 3.86% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 16.96 |
Income Statement
In the last 12 months, BioLineRx had revenue of $1.18 million and -$1.18 million in losses. Loss per share was -$0.00.
| Revenue | 1.18M |
| Gross Profit | 950,000 |
| Operating Income | -10.29M |
| Pretax Income | -2.03M |
| Net Income | -1.18M |
| EBITDA | -10.06M |
| EBIT | -10.29M |
| Loss Per Share | -$0.00 |
Full Income StatementBalance Sheet
The company has $20.88 million in cash and $10.15 million in debt, with a net cash position of $10.73 million or $0.00 per share.
| Cash & Cash Equivalents | 20.88M |
| Total Debt | 10.15M |
| Net Cash | 10.73M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 23.35M |
| Book Value Per Share | 0.01 |
| Working Capital | 11.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.07 million and capital expenditures -$25,000, giving a free cash flow of -$8.10 million.
| Operating Cash Flow | -8.07M |
| Capital Expenditures | -25,000 |
| Depreciation & Amortization | 227,000 |
| Net Borrowing | -5.01M |
| Free Cash Flow | -8.10M |
| FCF Per Share | -$0.00 |
Full Cash Flow StatementMargins
Gross margin is 80.51%, with operating and profit margins of -871.78% and -99.58%.
| Gross Margin | 80.51% |
| Operating Margin | -871.78% |
| Pretax Margin | -171.69% |
| Profit Margin | -99.58% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -105.76% |
| Shareholder Yield | -105.76% |
| Earnings Yield | -10.93% |
| FCF Yield | -75.34% |
Analyst Forecast
The average price target for BioLineRx is $19.00, which is 771.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.00 |
| Price Target Difference | 771.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 30, 2025. It was a reverse split with a ratio of 1:40.
| Last Split Date | Jan 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
BioLineRx has an Altman Z-Score of -13.64 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.64 |
| Piotroski F-Score | 3 |
